Home › Blog › Men's health › Enlarged prostate after 45

Men's health · Prostate guide

Enlarged Prostate After 45: What Are Your Options And What Does The Evidence Actually Show?

The prostate grows with age. What that does to your urine stream, how to put a number on it yourself, and which of the plant extracts on the shelf have real human trial data behind them.

Short answer

An enlarged prostate is not unusual after 45 and becomes more common with age. The evidence points to three levers you control: scoring your symptoms with a validated questionnaire, staying physically active, and choosing plant extracts that have real trial data behind them. None is proven to shrink the gland. The realistic target is supporting normal urinary flow.

Before you read on

I am not a doctor, urologist or pharmacist. I write from published research. See your own doctor before you start or stop any supplement, and get any urinary or prostate symptom checked in person.

Some links on this site are affiliate links. If you buy through one of our review pages we may earn a commission, at no extra cost to you. It does not change what the studies say or what we write here.

What is actually happening to the prostate after 45?

The prostate keeps growing through adult life, and as men get older that growth can start to squeeze the tube urine passes through. What you notice is a plumbing problem, not a pain problem.

The gland sits below the bladder and wraps around the urethra, the channel that carries urine out. When prostate tissue expands it narrows that channel from the outside, the bladder muscles have to work harder to push urine through, and over time they may weaken and be unable to empty completely.1 That is how the change tends to show up: a stream that takes a moment to start, a weaker stream than before, and a bladder that wants emptying again far too soon. This is common with ageing, not something you did wrong.

A typical prostate compared with one enlarged by years of growth Schematic. The prostate wraps around the urethra just below the bladder. As the gland enlarges it narrows the urethra, so the bladder has to push harder to empty. Typical After years of growth Bladder Prostate Urethra Bladder Enlarged Narrowed channel
Schematic, not to scale. The gland wraps the urethra just below the bladder. When it expands it squeezes that channel from the outside, which is why the change shows up as a weaker stream and a bladder that empties less completely rather than as pain.

The numbers reset expectations. The National Institute of Diabetes and Digestive and Kidney Diseases, part of the US National Institutes of Health, states that benign prostatic hyperplasia "affects 5% to 6% of men ages 40 to 64 and 29% to 33% of those ages 65 and older".1 In the 40 to 64 age range this is a minority experience (NIDDK puts it at 5% to 6%). By the mid-sixties it is close to one man in three.

A large 2026 cohort put a time frame on it. The China Health and Retirement Longitudinal Study followed 6,713 men aged 45 or older who had no urinary symptoms at the start, for a median of seven years. For a symptom-free 45-year-old, the predicted chance of developing them was 16.7% over the next 10 years, 30.6% over 20 years and 42.2% over 30 years.10 These were Chinese men, tracked through surveys, so read the exact figures as a direction rather than a personal forecast.

Gland size and symptom severity do not always line up. NIDDK puts it plainly: symptoms "may not be directly related to the size of your prostate", and a slightly enlarged gland can sometimes cause more symptoms than a large one.1 Symptoms are also what guide care. The American Urological Association's 2026 guideline says it in one line: "Bothersome LUTS is the main reason patients seek treatment and generally drives management decisions." LUTS stands for lower urinary tract symptoms.11

A man in a cap and dark jacket, seen from behind, walking along a gravel path beside a stone wall with hills in the distance
Benign prostate enlargement is common with ageing, not something you did wrong.

What symptoms should I track?

Track the seven urinary symptoms that clinicians score, and separately know the short list of warning signs that mean you stop reading and book an appointment.

NIDDK describes the pattern this way: you may have "trouble starting a urine stream or emptying your bladder, a weak or interrupted urine stream, or dribbling at the end of urination, nocturia, urinary urgency, urinary frequency, pain during urination".1 Nocturia is getting up at night to urinate. It is worth counting carefully, because every trip breaks your sleep.

Write down what you actually experience rather than a general impression. Count night-time trips for three nights in a row, and notice whether the delay before your stream starts is getting longer month to month. Impressions drift. Counts do not.

Signs that need a doctor, not a supplement

  • Blood in the urine or semen.
  • Pain or burning when you urinate, or fever and chills.
  • Being unable to urinate at all, which is an emergency.
  • Symptoms that appeared suddenly or are getting worse quickly.
  • Any new urinary symptom you have not had checked in person.

Those can point to infection or another condition that needs proper treatment. A supplement is not the answer to any of them.

One question is worth settling early: does an enlarged prostate raise the risk of prostate cancer? Cleveland Clinic states that research shows having BPH does not increase your risk of developing prostate cancer. The two do share symptoms, though, so a man with BPH can have undetected prostate cancer at the same time.9 That is one more reason to have a new symptom checked in person.

How do I score my own urinary symptoms?

Use the International Prostate Symptom Score. It is seven questions, each scored 0 to 5, giving a total from 0 to 35. That total is a useful number to take to an appointment and to compare against later.

It began as the American Urological Association symptom index, published by Barry and colleagues in the Journal of Urology in 1992. The paper describes an index of "7 questions covering frequency, nocturia, weak urinary stream, hesitancy, intermittence, incomplete emptying and urgency", validated in 210 men with an enlarged prostate against 108 controls.2 A 1996 study in Urology describes the IPSS as "originally known as the American Urological Association Score", with questions 1 to 7 giving the total symptom score and an eighth question covering quality of life.13

#What the question asks about the past monthScore
1Incomplete emptying: how often did you feel your bladder had not emptied completely after you finished?0 to 5
2Frequency: how often did you have to urinate again less than two hours after you last finished?0 to 5
3Intermittency: how often did you stop and start again several times while urinating?0 to 5
4Urgency: how often did you find it difficult to postpone urinating?0 to 5
5Weak stream: how often did you have a weak urinary stream?0 to 5
6Hesitancy: how often did you have to push or strain to get the stream started?0 to 5
7Nocturia: how many times did you get up to urinate between going to bed and getting up?0 to 5

Add the seven answers. The 2023 Cochrane review of saw palmetto describes the scale plainly as running from 0 to 35, with higher scores meaning worse symptoms, and most trials in the saw palmetto review enrolled men scoring 8 to 19.3

The International Prostate Symptom Score scale, 0 to 35 A 0 to 35 track. Higher scores mean more bothersome symptoms. The stretch from 8 to 19 is highlighted, because most trials in the 2023 saw palmetto review enrolled men scoring in that range. IPSS total score (higher means more bothersome symptoms) 8 to 19 081935 Most trials in the saw palmetto review enrolled men scoring 8 to 19
How the score runs. Seven questions, each scored 0 to 5, for a total of 0 to 35. Higher means more bothersome symptoms. The highlighted range is where most men in the saw palmetto trials scored.

Two things make the number more useful than it looks. It moves when something real changes: Barry's validation showed the index falling from a mean of 17.6 before surgery to 7.1 four weeks after.2 And most trials in the saw palmetto review enrolled men scoring 8 to 19, so if you score in that range that research was done on men like you.3 CAMUS, for example, enrolled men aged 45 or older scoring between 8 and 24.4

Score yourself today and write the number down with the date. You will want it again in four weeks.

Does diet and daily routine change any of this?

Physical activity has pooled data from tens of thousands of men behind it, and the association is not trivial.

Parsons and Kashefi pooled the evidence in European Urology in 2008. Eleven studies covering 43,083 men met their criteria, and eight of those, covering 35,675 men, went into the pooled analysis. Compared with sedentary men, the odds ratios for an enlarged prostate or lower urinary tract symptoms were 0.70 for light activity, 0.74 for moderate activity and 0.74 for heavy activity. The moderate and heavy results reached statistical significance; the light-activity figure did not.5

Men with moderate or heavy activity had roughly a quarter lower odds of having these symptoms. These were observational studies, so they show a consistent association rather than proving cause.

The picture has been revisited since. A 2026 update by Branco and colleagues in Current Urology Reports gathered 19 human studies. Of the six that looked at structured exercise, four found a protective link, and moderate-intensity exercise appeared to protect more than high-intensity work. Of the 14 that looked at general physical activity, seven found a protective link, and there most of the studies pointed to high-intensity activity as giving the greatest benefit. The authors call the evidence inconsistent and ask for randomised trials.12 Walking costs nothing, which makes it an easy place to start.

Waistline belongs in the same column. In the 2026 CHARLS cohort above, body-mass index and waist circumference were among the independent predictors of new symptoms, and the authors flag central obesity as a modifiable factor while noting that cause and effect still need testing.10

NIDDK's own daily-routine advice is unglamorous and free: "drink fewer liquids, particularly before you go out in public or go to bed, avoid or limit alcohol and caffeine, be physically active, empty your bladder completely when you urinate, use the restroom often and don't try to hold urine for long periods of time".1 Those steps are aimed at the day-to-day symptoms, which is the part you feel.

Which plant extracts have actual trial data?

Three carry randomised, placebo-controlled human data on urinary symptoms: beta-sitosterol, pygeum and nettle root. A fourth, saw palmetto, has been tested in 27 studies (19 of the herb alone) and showed little to no benefit when it was given on its own.

My aim here is not to rank them. It is to show you how to read a trial against the seven answers you just scored. The trials counted things you can track yourself: stream strength, how completely the bladder empties, night-time trips and the symptom score. The table at the end of this section puts the headline figures side by side. For the full trial breakdown of each extract, see our guide to which prostate supplement ingredients have real clinical evidence.

Beta-sitosterol

The evidence is a Cochrane review of four placebo-controlled trials. Its flow and emptying results are in the table, and the 4.9-point symptom difference comes only from the two studies that used the IPSS. Daily amounts ranged from 60 mg to 195 mg in the three trials that used non-glucosidic beta-sitosterol.6

The same review is clear that beta-sitosterol did not significantly reduce gland size, and that its long-term effectiveness and safety are not established. What it measured is flow and emptying, which you notice, rather than the dimensions of the gland, which you do not.

Pygeum africanum

The evidence is a second Cochrane review, of 18 randomised trials. Its figures, including night-time trips, are in the table. The authors' own caveat deserves repeating: the studies were small, averaged 64 days, used varied preparations, and rarely used standardised outcome measures. A real signal recorded in short studies rather than a settled case.7

Nettle root

The evidence is one six-month, double-blind, placebo-controlled randomised trial by Safarinejad (Journal of Herbal Pharmacotherapy, 2005) in 620 men, of whom 558 completed it. Its symptom and flow figures are in the table. Prostate size, measured by ultrasound, fell modestly from 40.1 to 36.3 cc on nettle root and did not change on placebo; the authors say further trials should confirm this.8

Saw palmetto

Tested on its own, saw palmetto did not beat placebo. In CAMUS (JAMA, 2011), symptom scores fell by 2.99 points on placebo and 2.20 on saw palmetto, even at up to three times the standard 320 mg daily dose for 72 weeks in 369 men.4 The 2023 Cochrane update, covering 27 studies and 4,656 men, reached the same verdict for the herb on its own.3

The word that matters is "alone". Those trials tested one berry extract by itself, and the same review looked at combinations separately, as the next section explains.

ExtractBest evidenceMen studiedWhat moved
Beta-sitosterolCochrane review, 4 randomised trials, 4 to 26 weeks6519Symptom score 4.9 points in the two studies that used the IPSS, peak flow +3.91 mL/s, residual volume 28.62 mL
Nettle rootSingle randomised trial, 6 months8620Symptom score 19.8 to 11.8, peak flow +8.2 mL/s, residual volume 73 to 36 mL
PygeumCochrane review, 18 trials, mean 64 days71,562Nocturia 19%, peak flow +23%, residual volume 24%
Saw palmetto aloneCochrane review 2023 and the CAMUS trial341,681 in the 9 low-risk-of-bias studies of the herb alone; 369 in CAMUSLittle to no difference from placebo when given by itself

Single extract or combination formula: what does the research say?

The research does not crown a winner. The figures quoted for each extract come from comparisons with placebo, each with its own measures and its own timeline, so they describe each ingredient rather than rank them.

The figures above each compare one extract with placebo. They do not compare the extracts with each other. The trials measured overlapping things, symptom scores, flow, emptying and night-time trips, in different groups of men over different lengths of time. That is useful context, not a league table.

Combinations have their own, thinner evidence. In the 2023 Cochrane review, the studies that gave saw palmetto together with other plant extracts came out at a mean difference of 2.41 points on the symptom score, and the authors graded that figure low certainty.3 They describe more uncertainty around combinations than around saw palmetto on its own, so the combination figure is an open question rather than a settled answer.

If you do look at a formula, read it for what it actually contains rather than for the word "combination". ProstaVive, for example, includes 200 mg of nettle root, alongside 50 mcg of vitamin D3 and 12 mg of zinc. Our ProstaVive review walks through what that label prints, so you can see exactly what is in the scoop.

There is a practical point too. The beta-sitosterol, pygeum and nettle root trials cited here ran from 4 weeks to 6 months, so whatever you choose has to be something you will still be taking months from now without thinking about it.

How long before you know if something is working?

Longer than a single month, and the trial lengths show why.

Look at the durations. Beta-sitosterol trials ran 4 to 26 weeks. Pygeum studies averaged 64 days. The nettle root trial ran a full six months before its final numbers were read.678 A 30-day check sits at the short end of that range.

In CAMUS, the placebo group improved by 2.99 points, so a change in your own score is not proof the product did it.4 That is why you need a baseline number and a fixed re-scoring schedule rather than a feeling.

We break the week-by-week picture down in our guide to how long prostate supplements take to work, including what tends to shift first and how to tell a real change from normal variation.

What can a doctor offer that a supplement cannot?

A doctor can offer prescription medicines and procedures that supplements cannot replace. NIDDK says an enlarged prostate (BPH) can be treated with watchful waiting, medicines or surgery, and lists alpha blockers, 5-alpha reductase inhibitors and phosphodiesterase-5 inhibitors among the medicines. It also describes minimally invasive procedures that remove enlarged prostate tissue or widen the urethra, and says surgery may be needed if medicines do not help, symptoms are severe or complications develop.1 Ask about both at your visit.

What should I plan for before I start?

Six practical decisions, made before you spend anything, that determine whether you end up with an answer or just a used tub.

  • Take your baseline today. Score the seven questions above and write the total and the date on your phone. Without it, any later comparison is a guess.
  • Plan a 90-day run, not a 30-day try. The trials above ran up to 6 months, and CAMUS ran 72 weeks. Plan 90 days inside the refund window.
  • Check that the refund window covers your run. A guarantee that expires before your trial period does is not much of a guarantee. Read the terms at checkout, not the headline.
  • Check with a pharmacist if you take a daily prescription, and show them the label before you start. Cleveland Clinic lists "Will these supplements affect any other medications or supplements that I’m taking?" among the questions to ask your provider.9
  • Change one thing at a time. Starting a supplement, a new exercise routine and a caffeine cut in the same week teaches you nothing about any of them.
  • Set the right target. The outcomes measured across this research are urinary flow, emptying and symptom scores, which are the things you can feel. None of it promises a smaller gland.

For side-by-side breakdowns of the individual formulas in this category, including what each label prints and what it leaves out, see our men's health supplement reviews.

Lid and logo of a ProstaVive tub
Your next step

Score your symptoms first, then read the label

Once your baseline number is written down, the useful question is what a formula actually puts in each scoop. Our review goes through the ProstaVive label: the label prints an amount for each line except the fruit and vegetable blend, which shows one combined 200 mg figure. It also explains how its 180-day refund policy works before you order.

See what is in each ProstaVive scoop

Frequently asked questions

Is an enlarged prostate after 45 normal?

It is not unusual. NIDDK reports that benign prostatic hyperplasia affects 5% to 6% of men ages 40 to 64, rising to 29% to 33% of men 65 and older, and calls it the most common prostate problem in men older than 50. Prostate growth itself is common with ageing. Whether it causes symptoms varies a lot from man to man, and NIDDK notes that symptoms may not be directly related to the size of the prostate.

Can you have an enlarged prostate in your 40s?

It happens, though it is less common than later in life. NIDDK notes that BPH rarely causes symptoms in men younger than 40 and estimates it affects 5% to 6% of men ages 40 to 64. A 2026 cohort of Chinese men put the predicted chance of new symptoms for a symptom-free 45-year-old at 16.7% over the next 10 years. Any new urinary symptom in your 40s is worth an in-person check, because other conditions can cause the same changes.

Does an enlarged prostate turn into prostate cancer?

No. Cleveland Clinic states that research shows having BPH does not increase your risk of developing prostate cancer. The two are separate conditions. The one thing to plan for is that they share symptoms, so a man with BPH can have undetected prostate cancer at the same time. That is why a weak stream or repeated night waking is worth having checked by a doctor rather than filed under ageing, and why anything you take for flow and comfort sits alongside that check rather than in place of it.

Can a supplement make an enlarged prostate go away?

No, and be wary of anything sold on that claim. The main outcomes measured in these trials are urinary flow, residual bladder volume and symptom scores. In the nettle root trial, prostate size measured by ultrasound fell modestly from 40.1 to 36.3 cc on nettle root and did not change on placebo, and the authors say further trials should confirm this. The Cochrane review of beta-sitosterol was explicit that it did not significantly reduce gland size, while it did improve flow and symptoms. Flow and comfort are the honest target.

Is an enlarged prostate dangerous, and what can a doctor do about it?

It can lead to complications, so it is worth having checked. NIDDK says an enlarged prostate can leave some urine in the bladder (urinary retention), and that other complications can include blood in the urine, urinary tract infections, kidney disease and bladder stones. It also says BPH can be treated with watchful waiting, medicines or surgery, depending on how severe your symptoms are and how they affect your quality of life. A doctor can offer prescription medicines and procedures that supplements cannot replace, so ask about both at your visit.

How do I score my urinary symptoms at home?

Answer the seven International Prostate Symptom Score questions covering incomplete emptying, frequency, intermittency, urgency, weak stream, hesitancy and nocturia. Each scores 0 to 5, so the total runs 0 to 35. Higher means more bothersome symptoms, and most trials in the 2023 saw palmetto review enrolled men scoring 8 to 19. Record the number and the date so you can compare later.

Does exercise actually help urinary symptoms?

The pooled evidence says men with moderate or heavy activity report fewer of these symptoms. Parsons and Kashefi reviewed 11 studies covering 43,083 men in European Urology, and in the eight studies they pooled, covering 35,675 men, the odds ratios were 0.74 for both moderate and heavy activity compared with sedentary men. These were observational studies, so they show a consistent association rather than proof of cause. A 2026 update by Branco and colleagues found the evidence inconsistent and asked for randomised trials.

Which plant extract has the strongest human data?

It depends on what you measure, because the figures cited here each compare one extract with placebo, not the extracts with each other. Beta-sitosterol was pooled in a Cochrane review of four randomised trials, with a 3.91 mL per second gain in peak flow. Nettle root has a six-month randomised study in 620 men. Pygeum was pooled across 18 shorter trials. Saw palmetto taken on its own showed little to no benefit in the 2023 Cochrane review and in the CAMUS trial.

Sources

  1. National Institute of Diabetes and Digestive and Kidney Diseases (NIH). Enlarged Prostate (Benign Prostatic Hyperplasia). Last reviewed June 2024. Prevalence by age, most common prostate problem in men older than 50, symptoms rare before 40, symptoms may not be directly related to prostate size, symptom list, complications, treatment options (watchful waiting, medicines, minimally invasive procedures, surgery) and self-care guidance. niddk.nih.gov
  2. Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT. The American Urological Association symptom index for benign prostatic hyperplasia. Journal of Urology. 1992 Nov;148(5):1549-57. Seven questions; validated in 210 patients and 108 controls; mean score fell from 17.6 to 7.1 after surgery. pubmed.ncbi.nlm.nih.gov/1279218
  3. Franco JVA, Trivisonno L, Sgarbossa NJ, Alvez GA, Fieiras C, Escobar Liquitay CM, Jung JH. Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement. Cochrane Database of Systematic Reviews. 2023 Jun 22;6(6):CD001423. 27 studies, 4,656 participants: 19 of Serenoa repens alone and 8 of combinations with other plant extracts; 9 low-risk-of-bias studies of Serenoa repens alone, 1,681 participants. Most studies enrolled men with moderate symptoms. IPSS range 0 to 35; moderate band 8 to 19. Mean difference 0.90 points for Serenoa repens alone; 2.41 points for combinations with other phytotherapy, low certainty. pubmed.ncbi.nlm.nih.gov/37345871
  4. Barry MJ, Meleth S, Lee JY, et al; CAMUS Study Group. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. JAMA. 2011 Sep 28;306(12):1344-51. 369 men aged 45 and over with symptom scores of 8 to 24, up to three times the 320 mg daily dose, 72 weeks. pubmed.ncbi.nlm.nih.gov/21954478
  5. Parsons JK, Kashefi C. Physical activity, benign prostatic hyperplasia, and lower urinary tract symptoms. European Urology. 2008 Jun;53(6):1228-35. 11 studies, 43,083 men; eight pooled studies, 35,675 men; pooled odds ratios versus sedentary of 0.70 (light), 0.74 (moderate) and 0.74 (heavy). pubmed.ncbi.nlm.nih.gov/18358592
  6. Wilt T, Ishani A, MacDonald R, Stark G, Mulrow C, Lau J. Beta-sitosterols for benign prostatic hyperplasia. Cochrane Database of Systematic Reviews. 2000;1999(2):CD001043. 519 men, 4 randomised placebo-controlled trials lasting 4 to 26 weeks; symptom score difference 4.9 points in the two trials that used the IPSS; peak flow +3.91 mL/s; residual volume 28.62 mL; daily doses of 60 mg to 195 mg in the three trials of non-glucosidic beta-sitosterol; prostate size not reduced. pubmed.ncbi.nlm.nih.gov/10796740
  7. Wilt T, Ishani A, Mac Donald R, Rutks I, Stark G. Pygeum africanum for benign prostatic hyperplasia. Cochrane Database of Systematic Reviews. 2002;1998(1):CD001044. 18 randomised trials, 1,562 men, mean duration 64 days; nocturia reduced 19%, residual volume 24%, peak flow increased 23%; doses 75 to 200 mg per day. pubmed.ncbi.nlm.nih.gov/11869585
  8. Safarinejad MR. Urtica dioica for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study. Journal of Herbal Pharmacotherapy. 2005;5(4):1-11. 620 men, six months; symptom score 19.8 to 11.8 versus 19.2 to 17.7 on placebo; peak flow +8.2 mL/s versus +3.4 mL/s; residual volume 73 to 36 mL; prostate size by ultrasound 40.1 to 36.3 cc on nettle root, no change on placebo, with the authors calling for further trials to confirm. pubmed.ncbi.nlm.nih.gov/16635963
  9. Cleveland Clinic. Benign Prostatic Hyperplasia (BPH). Research shows BPH does not increase the risk of developing prostate cancer; the two share symptoms, and a man with BPH can have undetected prostate cancer at the same time. It also lists "Will these supplements affect any other medications or supplements that I’m taking?" among the questions to ask your healthcare provider. my.clevelandclinic.org
  10. Lv C, Zhao M, Meng Q, et al. Incidence and risk factors of LUTS associated with benign prostatic hyperplasia among Chinese men: findings from the CHARLS cohort. Scientific Reports. 2026 Feb 26;16(1):11155. 6,713 men aged 45 and over, free of symptoms at baseline, median follow-up seven years; predicted cumulative risk for a 45-year-old of 16.7%, 30.6% and 42.2% over 10, 20 and 30 years; body-mass index and waist circumference among independent predictors. pubmed.ncbi.nlm.nih.gov/41748730
  11. Goueli R, Badlani GH, Welliver C, et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline (2026) Part I: Presentation and Evaluation. Journal of Urology. 2026 Aug;216(2):143-151. pubmed.ncbi.nlm.nih.gov/42095481
  12. Branco F, Rocha-Rodrigues S, Ribal MJ, Ribeiro R. Exercise and Physical Activity as Modifiable Risk Factors for Benign Prostatic Hyperplasia: An Update. Current Urology Reports. 2026 Jul 21;27(1):33. 19 human studies; four of six exercise studies and seven of 14 physical activity studies reported a protective association; moderate intensity appeared more protective for structured exercise, while most physical activity studies pointed to high intensity for the greatest benefit. pubmed.ncbi.nlm.nih.gov/42479233
  13. Plante M, Corcos J, Gregoire I, Belanger MF, Brock G, Rossingol M. The international prostate symptom score: physician versus self-administration in the quantification of symptomatology. Urology. 1996 Mar;47(3):326-8. The IPSS, originally known as the American Urological Association Score; total symptom score from questions 1 to 7, quality of life from question 8. pubmed.ncbi.nlm.nih.gov/8633396
Ray Delgado

About the author: Ray Delgado

I'm Ray Delgado, and I'm 46. After 40 I started paying attention to the health questions men my age actually ask, and went looking for straight answers. The clearest ones were sitting in the research, so I started reading the actual studies, and then writing this: plain-English breakdowns of what the research shows on prostate and men's health supplements, what the labels leave out, and what is worth paying for. No fear-mongering, no miracle cures. I bought ProstaVive myself, which is why I wrote about it.

Not medical advice. I am not a doctor, urologist or pharmacist. Updated 24 October 2026. This article contains links to our review pages, which carry affiliate links.

Affiliate disclosure: some links on this site are affiliate links. If you buy through one of our review pages we may earn a commission, at no additional cost to you. This does not affect what we write or which studies we cite. This article is general information, not medical advice, and it is not a diagnosis. Statements about dietary supplements have not been evaluated by the Food and Drug Administration, and supplements are not intended to diagnose, treat, cure or prevent any disease. Talk to a doctor before starting a supplement, especially if you take medication or have a health condition, and get any urinary or prostate symptom assessed in person.